Cantor Fitzgerald Maintains Prothena Corp (NASDAQ:PRTA) As a “Overweight”; They Now Have a Target Of $18

June 15, 2018 - By Kurt Siggers

Prothena Corporation plc (NASDAQ:PRTA) Logo

Investors sentiment decreased to 0.89 in 2018 Q1. Its down 0.29, from 1.18 in 2017Q4. It fall, as 30 investors sold Prothena Corporation plc shares while 35 reduced holdings. 22 funds opened positions while 36 raised stakes. 29.85 million shares or 4.71% less from 31.32 million shares in 2017Q4 were reported.

4 are owned by Signaturefd Llc. Carroll reported 1 shares or 0% of all its holdings. Ameriprise has 8,928 shares. 322,470 were accumulated by Voya Inv Lc. Parallax Volatility Advisers Ltd Partnership owns 81,233 shares. Westfield Cap Limited Partnership holds 0.09% or 309,819 shares in its portfolio. Stratos Wealth Prtnrs Limited invested in 0% or 9 shares. 238,499 are owned by Goldman Sachs. Axa invested 0.02% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). State Street owns 1.75 million shares for 0.01% of their portfolio. Numerixs Inv Tech invested in 1,200 shares. Barclays Public Limited Company holds 0% in Prothena Corporation plc (NASDAQ:PRTA) or 114,741 shares. Dekabank Deutsche Girozentrale holds 0% or 15,850 shares. The New York-based Blackrock has invested 0.01% in Prothena Corporation plc (NASDAQ:PRTA). Swiss Bancshares accumulated 66,400 shares.

Prothena Corp (NASDAQ:PRTA) Rating Reaffirmed

In analysts report made public on Friday, 15 June, The “Overweight” rating of Prothena Corp (NASDAQ:PRTA) shares was maintained by Analysts at Cantor Fitzgerald, who now has a $18 price target on the stock. Cantor Fitzgerald’s price target suggests a possible upside of 21.21 % from the last stock close price of the company.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Among 9 analysts covering Prothena Corp (NASDAQ:PRTA), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Prothena Corp has $70.0 highest and $1200 lowest target. $40’s average target is 169.36% above currents $14.85 stock price. Prothena Corp had 15 analyst reports since December 20, 2017 according to SRatingsIntel. Barclays Capital downgraded Prothena Corporation plc (NASDAQ:PRTA) on Monday, April 23 to “Hold” rating. The rating was maintained by Nomura with “Buy” on Tuesday, April 24. On Monday, May 21 the stock rating was downgraded by Barclays Capital to “Sell”. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Overweight” rating given on Tuesday, April 24 by Cantor Fitzgerald. Oppenheimer maintained Prothena Corporation plc (NASDAQ:PRTA) rating on Wednesday, March 21. Oppenheimer has “Buy” rating and $70.0 target. The firm earned “Buy” rating on Wednesday, December 20 by Cantor Fitzgerald. On Monday, April 23 the stock rating was downgraded by RBC Capital Markets to “Hold”. On Thursday, April 5 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Hold” rating by Jefferies given on Monday, April 23. The company was maintained on Thursday, February 15 by Cantor Fitzgerald.

The stock increased 1.02% or $0.15 during the last trading session, reaching $14.85. About 863,423 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has declined 73.35% since June 15, 2017 and is downtrending. It has underperformed by 85.92% the S&P500.

Analysts await Prothena Corporation plc (NASDAQ:PRTA) to report earnings on August, 14. They expect $-0.92 EPS, down 100.00 % or $0.46 from last year’s $-0.46 per share. After $-1.26 actual EPS reported by Prothena Corporation plc for the previous quarter, Wall Street now forecasts -26.98 % EPS growth.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $591.36 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

More notable recent Prothena Corporation plc (NASDAQ:PRTA) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have …” on May 22, 2018, also Globenewswire.com with their article: “SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100000 From …” published on May 24, 2018, Globenewswire.com published: “UPDATE — The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Fluor …” on June 15, 2018. More interesting news about Prothena Corporation plc (NASDAQ:PRTA) were released by: Streetinsider.com and their article: “Pre-Open Stock Movers 05/21: (MBFI) (NBRV) (SHLD) Higher; (PRTA) (QD) (APPF) Lower (more…)” published on May 21, 2018 as well as Seekingalpha.com‘s news article titled: “Eidos Therapeutics files for initial public offering” with publication date: May 25, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: